SCHEMBL12418537

SCHEMBL12418537

CCCCOc1ccc2c(c1)CCC1C2CC[C@]2(C)C(=O)C(CC(=O)OCC)CC12

nearest known ligand 0.78

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSD17B1 P14061 8/20 0.78
KDM4E B2RXH2 1/20 0.52
ALDH1A1 P00352 1/20 0.52
ESR1 P03372 1/20 0.48
ZAP70 P43403 2/20 0.47
STS P08842 3/20 0.47
MAPT P10636 2/20 0.46
LMNA P02545 1/20 0.46
RECQL P46063 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
MEN1 O00255 1/20 0.46
THRB P10828 1/20 0.46
KMT2A Q03164 1/20 0.46
HRH3 Q9Y5N1 2/20 0.46
ABCC4 O15439 1/20 0.46
CYP2C9 P11712 1/20 0.46
ABCC1 P33527 1/20 0.46
SLCO1B1 Q9Y6L6 1/20 0.46
KCNH2 Q12809 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12418539 0.91 HSD17B1 (0.63) HSD17B1KDM4EALDH1A1STSMAPT
SCHEMBL12379510 0.89 HSD17B1 (0.76) HSD17B1KDM4EALDH1A1STSMAPT
SCHEMBL12379501 0.88 HSD17B1 (1.00) HSD17B1ESR1STSMAPTLMNA
SCHEMBL12418389 0.86 HSD17B1 (0.67) HSD17B1ESR1STS
SCHEMBL12418540 0.82 HSD17B1 (0.53) HSD17B1KDM4EALDH1A1ZAP70HRH3
SCHEMBL12418333 0.80 HSD17B1 (0.63) HSD17B1KDM4EALDH1A1STSMAPT
SCHEMBL7124873 0.79 HSD17B1 (0.64) HSD17B1KDM4EALDH1A1ESR1STS
SCHEMBL7124870 0.79 HSD17B1 (0.64) HSD17B1KDM4EALDH1A1ESR1STS
SCHEMBL12379505 0.79 USP2 (0.64) HSD17B1KDM4EALDH1A1STSMAPT
SCHEMBL12418958 0.78 HSD17B1 (0.82) HSD17B1ESR1STSMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8003783-B2 Steroid 17 beta -hydroxysteroid dehydrogenase inhibitors substituted with one or more oxime groups, especially aromatase inhibitors used in the treatment of endocrine-dependent tumors, especially breast cancer STERIX LIMITED (GB) 2011-08-23 US disclosed